Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $917

Benzinga · 04/14 18:03
Goldman Sachs analyst Salveen Richter maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $1019 to $917.